- What Is It?
- Symptoms & Signs
Facts you should know about polymyalgia rheumatica (PMR)
- Polymyalgia rheumatica (PMR) is a disease that causes pain and stiffness in muscles and joints, low-grade fever, and weight loss.
- Health care professionals diagnose PMR by characteristic common symptoms associated with abnormal blood testing for inflammation.
- Treatment of PMR involves taking low doses of cortisone medications.
What is polymyalgia rheumatica?
Polymyalgia rheumatica is a disease of the muscles and joints characterized by muscle pain (myalgia) and stiffness, affecting both sides of the body, and involving the shoulders, arms, neck, and buttock areas. People with the disease are typically over 50 years of age. Polymyalgia rheumatica is abbreviated PMR.
What are polymyalgia rheumatica causes and risk factors?
The cause of the condition is not known. Recent research has indicated that genetic (inherited) risk factors play a role in who becomes afflicted with the illness. Theories include viral stimulation of the immune system in genetically susceptible individuals. Rarely, the disease is associated with a cancer. In this setting, the cancer may be initiating an inflammatory immune response to cause the polymyalgia rheumatica symptoms.
What are common symptoms and signs of polymyalgia rheumatica?
The onset of the disease can be sudden. A patient may have a healthy history until awakening one morning with stiffness and pain of muscles and joints throughout the body, particularly in the upper arms, hips, neck, and shoulders. These pains can lead to a sensation of weakness and loss of function. Sometimes there is also muscle tenderness with PMR. These clinical symptoms persist and often include an intense sensation of fatigue. Some patients notice a gradual loss of appetite accompanied by weight loss and lack of energy. Depression can occur.
How do health care professionals make a diagnosis of polymyalgia rheumatica?
The diagnosis of the disorder is suggested by the health history and physical examination. A health care professional frequently notes muscle tenderness and that the motion of the shoulders is limited by pain. The joints are usually not swollen. However, signs such as swelling of the small joints of the hands, wrists, and/or knees can occur. Blood testing for inflammation is generally abnormal, as indicated by a significant elevation in the erythrocyte sedimentation rate (sed rate or ESR) and/or C-reactive protein. There are no specific tests, however, for the condition and X-rays are normal. The diagnosis is based on the characteristic history of persisting muscle and joint pain and stiffness associated with elevated blood tests for inflammation, such as the ESR. It is also not unusual for patients to have slight elevations of liver blood tests.
What is the medical treatment for polymyalgia rheumatica?
Doctors direct their medical treatment of PMR toward reducing pain and inflammation. While some patients with mild symptoms can improve with nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin or ibuprofen (Motrin, Advil), most patients respond best to low doses of corticosteroids (such as prednisone or prednisolone). Not infrequently, a single day of cortisone medicine eases many of the symptoms! In fact, the rapid, gratifying results with low dose corticosteroids is characteristic of the condition.
The corticosteroid dose is gradually reduced while the doctor monitors the symptoms and normalization of the blood ESR. Reactivation of symptoms can require periodic adjustments in the prednisone dosage. Most patients are able to completely wean from the corticosteroid within several years. Some patients require longer-term medical treatment. Occasionally, patients have recurrence years after the symptoms have resolved. The ideal prednisone dosing regimen continues to be sought by clinical researchers.
What is the prognosis for patients with polymyalgia rheumatica?
The outlook for patients with isolated polymyalgia rheumatica is ultimately very good.
One of the keys to successful treatment of polymyalgia rheumatica is gradual, and not rapid, tapering of the medicines. This can avoid unwanted flare-ups of the disease.
Because the medicines prednisone and prednisolone are associated with potential bone toxicity, causing osteoporosis, patients should consider calcium and vitamin D supplementation. Bone mineral density testing should be performed in appropriate patients, and doctors may consider prescribing osteoporosis medicines, such as estrogen, alendronate (Fosamax), and risedronate (Actonel) for some.
Is it possible to prevent polymyalgia rheumatica?
What are polymyalgia rheumatica complications?
Polymyalgia rheumatica can lead to loss of function of joints if untreated. This generally is temporary, but frozen shoulders can be a further medical complication. Additional complications can result from medications used to treat polymyalgia rheumatica. These include stomach bleeding or kidney impairment from nonsteroidal anti-inflammatory drugs and cataracts, bruising of skin, and osteoporosis from cortisone medications. Therefore, the lowest possible doses of medications are best.
Polymyalgia rheumatica can occur in association with giant cell arteritis (temporal arteritis). Giant cell arteritis is a potentially more serious condition. It can also occur, as mentioned above, in association with a cancer. The prognosis in this setting is based on the ability to cure the cancer. The polymyalgia rheumatica symptoms resolve with resolution of the cancer.
Joint Problems Resources
Health Solutions From Our Sponsors
Buttgereit, F., C. Dejaco, E.L. Matteson, and B. Dasgupta. "Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review." JAMA 315 (2016): 2442.
Caporali, R., M.A. Cimmino, G. Ferraccioli, et al. "Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial." Ann Intern Med 141 (2004): 493.
Chou, Chung-Tei, and H. Ralph Schumacher, Jr. "?Clinical and pathologic studies of synovitis in polymyalgia rheumatica." Arthritis and Rheumatism 27.10 Oct. 1984: 1107-1117.
Cid, M.C., et al. "Polymyalgia rheumatica: a syndrome associated with HLA-DR4 antigen." Arthritis Rheum 31.5 May 1988: 678-682.
Cutolo, M., M.A. Cimmino, and A. Sulli. "Polymyalgia Rheumatica vs Late-Onset Rheumatoid Arthritis." Rheumatology 48.2 Feb. 1, 2009: 93-95.
Dejaco, C., Y.P. Singh, P. Perel, et al. "Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica." Ann Rheum Dis 74 (2015): 1808.
Firestein, Gary S., et al. Kelley's Textbook of Rheumatology, 9th Edition. Philadelphia, PA: Saunders, 2013.
González-Gay, M.A., C. García-Porrúa, M. Vázquez-Caruncho, et al. "The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study." J Rheumatol 26 (1999): 1326.
Hernández-Rodríguez, J., M.C. Cid, A. López-Soto, et al. "Treatment of polymyalgia rheumatica: a systematic review." Arch Intern Med 169 (2009): 1839.
Kremers, H.M., M.S. Reinalda, C.S. Crowson, et al. "Relapse in a population based cohort of patients with polymyalgia rheumatica." J Rheumatol 32 (2005): 65.
"Polymyalgia Rheumatica." March 2017. American College of Rheumatology. <https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Polymyalgia-Rheumatica>.
Salvarani, C., F. Cantini, and G.G. Hunder. "Polymyalgia rheumatica and giant-cell arteritis." Lancet 372.9634 July 19, 2008: 234-245.
Salvarani, C., F. Cantini, L. Niccoli, et al. "Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study." Arthritis Rheum 53 (2005): 33.